THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or ...
The increasing frequency and severity of environmental disasters necessitate robust health-care system adaptation strategies. Recent wildfire events in and around Los Angeles County, CA, USA, are ...
NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...
CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback